Switzerland’s Ferring is diving deep into the microbiome, looking at a range of potential therapy platforms including bacteriophage and probiotics. Its CSO believes a microbiome-based therapeutic approach could benefit dermatological and women’s health conditions, as well as gastro-intestinal disorders.

Israel’s RondinX is analyzing the microbiome with specific algorithms in order to develop new therapeutic approaches to disease.

The Switzerland-based company targets a novel therapeutic area still small enough for it to make a difference, the development of bacteriophage therapies for disorders thought to be associated with abnormal bacterial microflora, with proof-of-principle studies to begin later this year.

After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO shared his views on the product and SillaJen’s future in the first part of this exclusive interview with PharmAsia News.